# Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

> **NCT00005831** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Bladder Cancer
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Squamous Cell Carcinoma of the Bladder
- Stage IV Bladder Cancer
- Transitional Cell Carcinoma of the Bladder

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **DRUG:** gemcitabine hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00005831
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2004-08
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005831, "Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00005831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*